Company intelligence / Profile preview
Chengdu Xilingyuan Pharmaceutical Co., Ltd.
Chengdu, Sichuan, Chinaxilinglab.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Xiling Lab has advanced its lead ADC candidate SMP‑656 targeting HER2 into Phase 1 clinical trials for solid tumors. The company’s pipeline includes more than seven best-in-class or first-in-class drug conjugate programs with a focus on oncology. Preclinical data show strong efficacy and safety profiles for their leading assets. The company also develops high-end generics such as Eribulin Mesylate Injection with international regulatory filings.
- Therapeutic areas
- OncologyImmunologyGastroenterology
- Modalities
- Antibody-drug conjugates (ADCs)Small moleculesPeptide-drug conjugates (PDCs)Antibody-PROTACs (DACs)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Kexing Biopharm holds exclusive commercialization rights to Eribulin Mesylate Injection from Xiling Lab in over thirty countries including Brazil, Argentina, Singapore, Thailand, Egypt, South Africa, India, Saudi Arabia etc.Multiple collaborations with biotech/pharma companies leveraging XL-XDC platform technology
Beyond the preview
Go deeper on Chengdu Xilingyuan Pharmaceutical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chengdu Xilingyuan Pharmaceutical Co., Ltd..